ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.750,92
-0,31%
S&P 500
5.308,13
0,09%
US Dollar vs BRL
5,1045
0,00%
Bitcoin
70.954,45
-0,69%
Brent Oil
82,765
-0,92%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Gilead Sciences Inc (GILD)

  7. Gilead Sciences Inc (GILD) Notícias

GILD

Gilead Sciences (GILD)

Gilead Sciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GILD
DataHoraFonteTítuloCódigoCompanhia
18/05/202409:30Business WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
14/05/202411:09Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyNASDAQ:GILDGilead Sciences Inc
09/05/202418:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
09/05/202417:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GILDGilead Sciences Inc
09/05/202417:05Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramNASDAQ:GILDGilead Sciences Inc
08/05/202417:58Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GILDGilead Sciences Inc
07/05/202409:30Business WireGilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024NASDAQ:GILDGilead Sciences Inc
30/04/202417:05Business WireGilead Sciences to Present at Upcoming Investor ConferencesNASDAQ:GILDGilead Sciences Inc
26/04/202409:00Business WireFDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIVNASDAQ:GILDGilead Sciences Inc
26/04/202408:47IH Market NewsExxon Mobil Net Profit Drops 28% to $8.22 Billion, Atlassian Surprises with Revenue Boost and Co-CEO Exit, and More in EarningsNASDAQ:GILDGilead Sciences Inc
25/04/202417:02Business WireGilead Sciences Announces First Quarter 2024 Financial ResultsNASDAQ:GILDGilead Sciences Inc
25/04/202408:53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:GILDGilead Sciences Inc
08/04/202417:05Business WireGilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024NASDAQ:GILDGilead Sciences Inc
28/03/202409:30Business WireFDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixNASDAQ:GILDGilead Sciences Inc
28/03/202408:00Business WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
22/03/202410:18Business WireGilead Sciences Announces Completion of Acquisition of CymaBayNASDAQ:GILDGilead Sciences Inc
18/03/202420:29Business WireCenter for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink GrantNASDAQ:GILDGilead Sciences Inc
11/03/202409:34Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:GILDGilead Sciences Inc
11/03/202409:24Business WireGilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender OfferNASDAQ:GILDGilead Sciences Inc
06/03/202418:30Business WireBiktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and ComorbiditiesNASDAQ:GILDGilead Sciences Inc
06/03/202412:25Business WireGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24NASDAQ:GILDGilead Sciences Inc
06/03/202410:00Business WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:GILDGilead Sciences Inc
05/03/202418:35Business WireNew Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19NASDAQ:GILDGilead Sciences Inc
05/03/202418:30Business WireGilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public HealthNASDAQ:GILDGilead Sciences Inc
29/02/202418:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GILDGilead Sciences Inc
27/02/202412:00Business WireGilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.NASDAQ:GILDGilead Sciences Inc
26/02/202418:05Business WireU.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing ResistanceNASDAQ:GILDGilead Sciences Inc
26/02/202410:30Business WireGilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024NASDAQ:GILDGilead Sciences Inc
23/02/202408:09Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:GILDGilead Sciences Inc
20/02/202418:31Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GILDGilead Sciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GILD

Seu Histórico Recente

NYSE
SBS
Companhia Sanea
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados